生命科学资讯

Aardvark's stock plummets on study pause; BioNTech heads to Phase 3 with DualityBio ADC

BioNTech advances DualityBio ADC into phase 3 with half the patients of Merck-Daiichi rival

BioNTech, UPenn team up for $50M seed fund

Genmab terminates Phase 3 lung cancer asset that BioNTech ditched

#SABCS25: BioNTech, BMS unwrap Phase 2 data for PD-L1xVEGF-A bispecific in breast cancer

ADCs on the rise: MilliporeSigma, Lonza invest in manufacturing while BioNTech adds CMOs ahead of FDA filing - Pharmaceutical Technology